Sp637

REMOTE TELEHEALTH AND PATIENT EDUCATION TO SUPPORT POST COVID IBD CARE

Date
May 7, 2023
Explore related products in the following collection:

Society: AGA

The Cochrane Gut group supports the production of high quality and methodologically rigorous reviews for a portfolio that includes upper GI, IBD and functional bowel disease topics in adults and children. In this session, three themes will be discussed that are very relevant to IBD care in a world recovering from and living with COVID. We will discuss immunization and susceptibility to infection in IBD patients. We will consider remote telehealth and patient education to support distance and patient directed care, Finally, we will consider Long-COVID in IBD. Each presentation will consider evidence synthesis in the form of Cochrane and none Cochrane reviews, as well as critically appraising the literature in a manner that supports transparency and clinical utility of findings. After each presentation, our panel of speakers and the moderators will discuss the relevance of the findings in relation to current practice and guidance and explore where gaps exist.

Tracks

Related Products

Thumbnail for PLACEHOLDER
PLACEHOLDER
Perturbations in the gut mucosal immune response contributes to IBD. Non-immune cell popopulations including epithelial and stromal cells also play an important role in intestinal inflammation…
Thumbnail for INTRODUCTION
INTRODUCTION
SOCIETY: AGA
Thumbnail for PANEL DISCUSSION: IMMUNISATION AND SUSCEPTIBILITY TO INFECTION IN PATIENTS WITH IBD
PANEL DISCUSSION: IMMUNISATION AND SUSCEPTIBILITY TO INFECTION IN PATIENTS WITH IBD
The Cochrane Gut group supports the production of high quality and methodologically rigorous reviews for a portfolio that includes upper GI, IBD and functional bowel disease topics in adults and children…
Thumbnail for MONITORING OF CALPROTECTIN IN INFLAMMATORY BOWEL DISEASE USING A SWEAT BASED WEARABLE DEVICE
MONITORING OF CALPROTECTIN IN INFLAMMATORY BOWEL DISEASE USING A SWEAT BASED WEARABLE DEVICE
Switching from originator to biosimilar infliximab (IFX) is effective and safe. However, data on multiple switching are scarce. The Edinburgh IBD unit has undertaken three switch programmes: (1) Remicade to CT-P13 (2016), (2) CT-P13 to SB2 (2020), and (3) SB2 to CT-P13 (2021)…